World Aids Day
The global challenge of HIV/AIDS remains one of the most pressing public health issues today. According to the latest data from UNAIDS, around 38.4 million people worldwide are living with HIV/AIDS, underlining the need for not only medical intervention but also comprehensive awareness, education, and social change. Despite the significant strides made in treatment and prevention, the confusion surrounding the relationship between HIV and AIDS still persists.
Young people have become influential advocates in the fight against HIV/AIDS. Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities. These young activists utilize digital platforms and peer-to-peer education to dispel myths, promote safe practices, and foster supportive environments for those affected by HIV/AIDS.
Dr Gowri Kulkarni, an expert in Internal Medicine, explains that while the terms HIV and AIDS are often used interchangeably, they are distinctly different. "HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that occurs when HIV severely damages the immune system," she clarifies. To understand the implications of these differences, it's important to explore the fundamental distinctions between the two.
HIV is the virus responsible for attacking the body’s immune system, specifically targeting CD4 cells, which are crucial for the body’s defense against infections. As HIV progresses, it destroys these cells, weakening the immune system over time. If left untreated, this continuous damage can lead to AIDS.
AIDS, on the other hand, is a syndrome, not a virus. Dr Kulkarni further elaborates that AIDS is a collection of symptoms and illnesses that emerge when the immune system is severely compromised due to prolonged HIV infection. It represents the most advanced stage of HIV, and is characterized by very low CD4 counts or the onset of opportunistic infections like tuberculosis, pneumonia, or certain cancers.
A key distinction to remember is that not everyone with HIV will progress to AIDS. Thanks to advancements in medicine, particularly antiretroviral therapy (ART), individuals living with HIV can manage the virus and maintain a healthy immune system for many years, or even decades, without ever developing AIDS. ART works by suppressing the virus to undetectable levels, effectively preventing the damage HIV would otherwise cause to the immune system.
Without treatment, however, HIV progresses through three stages:
- Acute HIV Infection: This stage occurs shortly after transmission and may include symptoms like fever, fatigue, and swollen lymph nodes.
- Chronic HIV Infection: Often asymptomatic or mildly symptomatic, the virus continues to damage the immune system but at a slower rate.
- AIDS: This is the final stage, marked by severe immune damage and the presence of infections that take advantage of the compromised immune defenses.
Another key distinction between HIV and AIDS is the way in which they are transmitted. HIV is highly contagious and can be transmitted through the exchange of bodily fluids such as blood, semen, vaginal fluids, and breast milk. It is primarily spread through unprotected sexual contact, sharing needles, or from mother to child during childbirth or breastfeeding.
AIDS, however, is not transmissible. It is not a disease that can be passed from one person to another. Rather, AIDS is the result of untreated, advanced HIV infection and is a direct consequence of the virus’s damage to the immune system.
HIV and AIDS are diagnosed through different methods. HIV is diagnosed through blood tests or oral swabs that detect the presence of the virus or antibodies produced by the immune system in response to the virus. Early detection of HIV is crucial, as it allows for timely intervention and treatment, which can prevent the virus from progressing to AIDS.
AIDS, on the other hand, is diagnosed using more specific criteria. Dr Kulkarni notes that the diagnosis of AIDS is made when the individual’s CD4 cell count falls below 200 cells/mm³, or when opportunistic infections or certain cancers (such as Kaposi's sarcoma or lymphoma) are detected. Diagnosing AIDS involves a more thorough assessment of the individual’s immune function and overall health, as opposed to just the detection of HIV.
The treatment goals for HIV and AIDS differ significantly, although both involve antiretroviral therapy (ART). For HIV, the primary treatment goal is to suppress the virus to undetectable levels, thus maintaining a strong immune system and preventing further transmission of the virus. People living with HIV can often live long, healthy lives if they adhere to ART.
For individuals diagnosed with AIDS, the treatment plan becomes more complex. While ART remains an essential part of managing the virus, treatment for AIDS also focuses on addressing the opportunistic infections and secondary health complications associated with severe immune suppression. The goal of treatment for AIDS is not only to manage the HIV virus but also to improve the quality of life and extend survival by treating these secondary health issues.
While the medical community has made great strides in managing HIV, the battle to curb its transmission is also a social and cultural issue. Dr Daman Ahuja, a public health expert, highlights that HIV/AIDS awareness and education are vital to reducing transmission rates and supporting those affected by the virus. "Young people, especially, have become key advocates in the fight against HIV/AIDS," says Dr Ahuja. "Research from UNICEF shows that youth-led initiatives can lower HIV transmission rates by as much as 45% in targeted communities."
Additionally, grassroots activism plays a significant role in raising awareness and addressing stigma. As the World Health Organization reports, community-based interventions have been proven to increase HIV testing rates and improve treatment adherence, which are crucial in the fight against the pandemic.
The ultimate goal of organizations like UNAIDS is to eliminate the HIV/AIDS pandemic by 2030. Achieving this requires global collaboration, from medical treatment advancements to public health strategies, education, and advocacy. Dr Kulkarni’s insight underscores the importance of early detection, treatment adherence, and community support in the fight against HIV/AIDS.
Dr Gowri Kulkarni is Head of Medical Operations at MediBuddy and Dr Daman Ahuja, a public health expert and has been associated with Red Ribbon Express Project of NACO between 2007-12.
Credit: Health Ministry
Prime Minister Narendra Modi today launched the nationwide Human Papillomavirus (HPV) vaccination campaign for girls aged 14 years from Rajasthan's Ajmer.
The initiative marks a decisive step towards eliminating cervical cancer through timely HPV vaccination. Cervical cancer remains the second most common cancer among women in India. Nearly 80,000 new cases and over 42,000 deaths are reported annually in the country.
"Today, I have had the opportunity to launch the HPV vaccine campaign from Ajmer. This campaign is an important step towards empowering women and daughters of this country,” PM Modi said.
“For us, this was a sensitive issue tied to the insult of our sisters and daughters, one that made them ill. That is why we resolved it at a crucial turning point in their mission,” he added.
The World Health Organization has also lauded India's mission to launch the HPV vaccine and prevent the risk of cervical cancer.
“We are leaving no stone unturned to ensure that the daughters of the country are healthy and prosperous. The objective of this initiative is the prevention of cervical cancer," the Prime Minister, earlier wrote in a post on social media platform X.
The nationwide program, based on expert recommendations of the National Technical Advisory Group on Immunization (NTAGI), will target girls aged 14 years.
At 14, the HPV vaccine offers maximum preventive benefit, well before potential exposure to the virus.
"By prioritizing prevention at the right age, the program is expected to provide lifelong protection and significantly reduce the future burden of cervical cancer in the country," the government said.
“The HPV vaccine works best at 9-14 years, before exposure, and when the immune response is strongest. Studies show effectiveness is highest in younger age groups and decreases with age,” Dr. Parmod Kumar, Associate Professor in Medical Oncology, AIIMS Jodhpur, shared on X.
Vaccination under the national program will be voluntary and free of cost.
The HPV vaccination will be conducted exclusively at designated government health facilities, including Ayushman Arogya Mandirs (Primary Health Centers), Community Health Centers, Sub-District and District Hospitals, and Government Medical Colleges.
Despite being preventable, cervical cancer continues to claim the life of a woman every two minutes globally, and the WHO South-East Asia Region bears nearly one-quarter of the global burden.
Dr. Catharina Boehme, Officer-in-Charge, WHO South-East Asia, stated that the introduction of HPV vaccination at a national scale in India "will have a far-reaching impact". It will accelerate progress not only for the country, but for the region and the world, she said.
“This landmark step, led at the highest level of government, reflects India’s strong commitment to protecting adolescent girls from cervical cancer," said Dr. Boehme.
With today’s milestone, nine of the 10 countries in the Region now include HPV vaccination in their national immunization programs.
The WHO global targets for 2030 include vaccinating 90 percent of girls by age 15, screening 70 percent of women by ages 35 and 45, and ensuring 90 percent of women with pre-cancer and invasive cancer receive appropriate treatment.
Credits: Canva
As we grow older, it is almost expected that memory will fade. Names slip. Dates blur. Thoughts take longer to form. Inside the aging brain, proteins can misfold and clump together, damaging cells and gradually eroding cognition. But not everyone follows this script.
Some people reach their 80s with memory and mental sharpness that rival those decades younger. Scientists call them “super-agers.” Now, new research published in Nature offers a possible explanation for why some brains hold up so remarkably well.
At the heart of the findings lies one of neuroscience’s most contested questions: can adult human brains grow new neurons?
Read: A Longevity Expert Who Studies 'Super Agers' Eats All THIS In A Day
For years, scientists have debated whether neurogenesis, the birth of new neurons, continues into adulthood. While it is well established in babies and young children, and in many animal species, evidence in adult humans has been mixed.
This new study adds weight to the idea that it does continue, even into advanced age.
Researchers examined brain tissue donated after death from several groups: younger adults with normal cognition, older adults with typical memory for their age, people with mild cognitive impairment, individuals with Alzheimer’s disease, and super-agers over 80 whose memory functioned like someone about 30 years younger.
They focused on the hippocampus, the brain’s memory hub and a region long suspected to be a birthplace for new neurons.
To detect neurogenesis, scientists looked for three types of cells: neural stem cells, neuroblasts, and immature neurons. In simple terms, stem cells are like infants, neuroblasts are adolescents, and immature neurons are on the brink of adulthood.
“We identified genetic markers for three key types of cells,” the researchers explained, tracing the pathway from stem cell to developing neuron.
All groups showed signs of these cell types. The difference lay in the numbers.
Super-agers had roughly twice as many new neurons as older adults with typical memory, and about two and a half times more than those with Alzheimer’s disease. In fact, their hippocampi contained even more immature neurons than the brains of younger adults.
“This paper shows biological proof that the aging brain is plastic,” Tamar Gefen told The New York Times. She added that this adaptability appears to persist “even into a person’s 80s.”
The immature neurons in super-agers also carried distinctive genetic and epigenetic signatures. According to Gefen, as quoted by The New York Times, “Super-aging happens not only because there’s more of these young cells, but because there is a type of genetic programming” that allows them to survive and resist age-related decline.
In other words, it is not just about quantity. It may also be about resilience.
The Alzheimer’s findings were equally intriguing.
People with Alzheimer’s actually had more neural stem cells than other older adults. But they had far fewer neuroblasts and immature neurons. This suggests that while the starting material was present, the developmental process stalled.
One interpretation is that neurogenesis becomes disrupted in Alzheimer’s. Stem cells may remain dormant, unable to mature into functioning neurons.
“If that’s true, that’s really opened up a new direction for the field,” Hongjun Song told The New York Times, suggesting that reactivating these dormant cells could one day become a therapeutic strategy.
It is an exciting possibility. Instead of only trying to prevent damage, scientists might be able to encourage regeneration.
The neurogenesis debate is far from settled.
Some researchers argue that methodological differences have led to conflicting conclusions over the years. Shawn Sorrells, who studies neurogenesis, told The New York Times that mapping how the hippocampus changes in people who age differently is “fantastically interesting and important,” but he cautioned that the findings should be validated using additional techniques.
Skepticism remains because detecting new neurons in adult human brains is technically difficult. Results often hinge on the markers and imaging tools used.
Even if this study does not end the debate, it opens new doors. If certain people naturally maintain robust neurogenesis into their 80s, researchers want to understand why. Is it genetics? Lifestyle? A combination of both?
Scientists are now exploring whether the special properties seen in super-agers’ immature neurons can be replicated or supported through medication or other interventions.
The bigger takeaway is hopeful. Aging does not necessarily mean inevitable cognitive collapse. The brain may retain more capacity for renewal than once believed.
If neurogenesis truly persists across the lifespan, the story of brain aging may need rewriting. Instead of focusing only on decline, researchers may increasingly look toward regeneration and resilience.
And for anyone worried about forgetting where they left their keys, that possibility feels quietly revolutionary.
Credit: Pixabay
In 2025, Andhra Pradesh reported 1,566 scrub typhus cases, and nine suspected deaths, according to data from the Integrated Health Information Platform, Integrated Disease Surveillance Programme (IDSP-IHIP) on 8 December. Followed by Karnataka with 1,870 cases, Tamil Nadu 7,308 cases, and Telangana, 309 cases. Scrub typhus cases have significantly increased from previous year. It is one of the deadliest infections affecting multiple organs, or even death. Early it was relevant to poeple working in fields, new studies show it migrating to human settlements.
Scrub typhus, also known as bush typhus, is a bacterial infection caused by bacteria infection, caused by bacterium Orientia tsutsugamushi. It is spread through bites of infected larval mites, Chiggers.
Most cases of scrub typhus occur in rural areas of Southeast Asia, Indonesia, China, Japan, the Indian subcontinent and northern Australia. Until now, it was believed that chiggers only lurked in the tall grasses of remote paddy fields or dense forests. Due to this, it is commonly known as "farmers' disease", only confined to the fields.
However, new PLOS study data revealed the opposite. The study is led by researchers from Christian Medical College (CMC) Vellore and international collaborators and suggests that the bulk of infections are now even occurring within human settlements.
The study monitored over 32 000 people in Tamil Nadu, which led to the conclusion that agricultural activities, long considered the primary risk factor, were only weakly associated with the disease in high-prevalence areas.
Risk for scrub typhus is significantly higher for those living in clustered houses or homes with fewer rooms. If the micro environment around the residence is unmaintained, gardens are patched, or even the damp corners of a courtyard, it could lead to breeding ground for the mites and the rodents that carry Chiggers.
It was once believed that working-age men were the most affected, but the new study tells otherwise. According to the new data, women over 60 are at the highest risk of infection.
As women spend most of their time in and around the home, due to household work, from the kitchen to the laundry, these activities are now the primary cross point of contact with infected mites.
As initial symptoms of infection, such as fever, headache, and muscle pain, are the same as viral flu or dengue, many first seek help from untrained practitioners or local pharmacies.
By the time they reach the hospital, the disease has already progressed to severe complications like acute respiratory distress syndrome (ARDS), Kidney failure, or Meningoencephalitis, which is inflammation of your meninges and brain at the same time, a life-threatening condition.
Not only this, the researchers revealed that nearly 10 percent of affected households exceed 25 percent of their income in the treatment.
For severe cases, the cost of treatment can be up to approximately INR 110,000, a staggering sum for rural and peri-urban families earning a fraction of that monthly.
Early intervention is necessary, as if a fever lasts more than two days, don't just treat it as "seasonal fever".
Consult a qualified doctor and specifically ask about scrub typhus. Infection can be treated with doxycycline common antibiotic, in the early stages. The case fatality rate in this study was 1.5 percent, hospital based studies in South India have previously recorded mortality rates as high 30 percent when treatment is delayed
© 2024 Bennett, Coleman & Company Limited